Trial Information

Summary: A Study of MabThera (Rituximab) Plus Sequential High-Dose Chemotherapy in Patients Newly Diagnosed With Mantle Cell Lymphoma

Status: Completed

Protocol Number: M39048

Sponsor: Roche S.p.a.

Company Division: Pharmaceutical

Official Scientific Title: An open-label study of the effect of MabThera plus high-dose sequential chemotherapy on durable clinical response in patients newly diagnosed with mantle cell lymphoma

Brief Summary: This study will evaluate the efficacy and safety of MabThera plus high-dose sequential chemotherapy in patients with a new diagnosis of mantle cell lymphoma. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals. Target sample size is 91.

Study Phase: II

Study Design / Study Details:

• Purpose: Treatment
• Allocation: Non-Randomized
• Masking: Open Label
• Control: Uncontrolled
• Assignment: Single Group
• Endpoints: Safety/Efficacy

Study Type:

Condition: Mantle Cell Lymphoma

Intervention Type: Drug

Intervention Name: rituximab[MabThera/Rituxan]

Primary Outcome: 1. Rate of durable complete clinical response, defined as >=24 months of relapse-free survival

Key Secondary Outcomes: 1. Rate of molecular response at treatment end and study end in patients with clinical complete remission; rate of complete response, partial response, stable disease, and progressive disease at treatment end and study end. AEs and laboratory parameters

Inclusion Criteria:

Exclusion Criteria:

Gender: Males or Females

Age Limits: Min: 18 Years Max: 60 Years

Accepts Healthy Volunteers: No

Trial Registration Date: 10/27/2005

Date Last Updated: 07/15/2008

Link To Trial Results

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 21, 2008 at 2:25:46 PM